Representative disulfide-containing ADCs.

ADC	Target	Cytotoxic payload	Clinical phase	Indications	Sponsor (licensee)	Ref.
Gemtuzumab ozogamicin (Mylotarg®)	CD33	Calicheamicin derivative	Approved	CD33-positive AML; relapsed or refractory AML	Pfizer	67
Inotuzumab ozogamicin (Besponsa®)	CD22	Calicheamicin derivative	Approved	Acute lymphoblastic leukaemia	Pfizer	69
Moxetumomab pasudotox (Lumoxiti®)	CD22	Pseudomonas exotoxin A	Approved	Relapsed or refractory hairy cell leukemia	AstraZeneca	70
Mirvetuximab soravtansine (IMGN853)	FRα	DM4	Phase III	Ovarian cancer	ImmunoGen	71
Coltuximab ravtansine (SAR3419)	CD19	DM4	Phase II	Diffuse large B-cell lymphoma	Sanofi	73 and 74
Lorvotuzumab mertansine (IMGN901)	CD56	DM1	Phase II stopped	Small cell lung cancer	ImmunoGen	78
AVE9633	CD33	DM4	Phase I stopped	AML	Sanofi	79
Indatuximab ravtansine (BT-062)	CD138	DM4	Phase I	Multiple myeloma	Biotest	80
Anetumab ravtansine (Bay-94-9343)	Mesotherin	DM4	Phase II	Pancreatic cancer	Bayer HealthCare	81
SAR-566658	CA6	DM4	Phase I	CA6-positive advanced STsa	Sanofi	82
SAR408701	CEACAM5	DM4	Phase I	Advanced STsa	Sanofi	83
SAR428926	LAMP1	DM4	Phase I	Advanced STsa	Sanofi	84
HKT288	Cadherin-6	DM4	Phase I	Epithelial ovarian cancer	Novartis Pharmaceuticals	85
Cantuzumab mertansine	CanAg	DM1	Phase I stopped	CanAg-expressing advanced STsa	ImmunoGen	86
IMGN242	CanAg	DM4	Phase II	Gastric or gastroesophageal (GE) junction cancer	ImmunoGen	87
IMGN388	Integrin αV	DM4	Phase I	STsa	ImmunoGen	88
BIIB015	Cripto	DM4	Phase I	Relapsed/refractory STsa	Biogen	89

^aSTs, solid tumors.